- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05388123
Low Dose Vemurafenib and Rituximab in Hairy Cell Leukemia
November 10, 2023 updated by: Scripps Health
A Single Arm Phase II Pilot Study of Low Dose Vemurafenib Plus Rituximab in the Front-line and Relapsed/Refractory Treatment of Hairy Cell Leukemia
The current standard-of-care for Hairy Cell Leukemia involves chemotherapy, with agents such as cladribine or pentostatin.
Chemotherapy is associated with infection, low blood counts and predisposition to future cancers.
This study tests a new yet previously validated drug combination for the treatment of hairy cell leukemia.
The treatment involves 8 weeks of treatment with an oral drug called vemurafenib and 8 doses of an intravenous medication called rituximab.
The goal of this study is to see whether this treatment is better tolerated and more effective than the currently used treatment in this disease.
In addition, this study uses a lower dose of vemurafenib than previous studies have used, with the goal of minimizing side effects from this medication.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
This is a single-center, open label, single arm, investigator-initiated phase II trial of the oral BRAF inhibitor, vemurafenib, plus rituximab in patients with previously untreated or relapsed and refractory HCL.
Eligible patients will receive vemurafenib at a dose of 240 mg orally twice daily (b.i.d.) continuously for 8 weeks.
Rituximab 375 mg/m2 will be administered concomitantly with vemurafenib every 2 weeks from the first day of treatment.
After completion of vemurafenib, the patient will receive rituximab 375 mg/m2 every 2 weeks for a total of 8 weeks.
The entire duration of treatment will be 16 weeks.
Six months after the initiation of the treatment, a bone marrow aspirate and biopsy will be performed for assessment of response and evaluation of minimal residual disease (MRD).
Study Type
Interventional
Enrollment (Estimated)
20
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Alan Saven, MD
- Phone Number: 8585548788
- Email: saven.alan@scrippshealth.org
Study Contact Backup
- Name: David J Hermel, MD
- Phone Number: 8585548788
- Email: hermel.david@scrippshealth.org
Study Locations
-
-
California
-
La Jolla, California, United States, 92037
- Recruiting
- Scripps Cancer Center
-
Principal Investigator:
- Alan Saven, MD
-
Contact:
- David J Hermel, MD
- Phone Number: 858-554-8788
- Email: hermel.david@scrippshealth.org
-
Sub-Investigator:
- David J Hermel, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 90 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- ≥ 18 years of age
- Histologically confirmed HCL that are BRAF V600E positive by IHC or NGS
- Patient's must meet the standard treatment initiation criteria, as defined by ANC ≤1.0, Hgb ≤ 10.0 or PLT ≤100K
- Patients can either have (1) not received any prior therapy for the disease or have had (2) failure to achieve any response to the initial purine analog-based therapy or (3) subsequent relapse after any prior therapy.
- ECOG performance status of 0-2
- Acceptable pre-study organ function during screening not exacerbated by Hairy Cell Leukemia. General thresholds should be a total bilirubin ≤ 1.5 times the upper limit of normal (ULN), aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5x ULN, and serum creatinine ≤ 1.5x ULN
- For women of childbearing potential, agreement to use acceptable methods of contraception
- For men with female partners of childbearing potential, agreement to use barrier contraception
- Negative serum pregnancy test within 7 days of commencement of treatment in premenopausal women.
- Ability to understand and willingness to sign a written informed consent document.
- Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures.
Exclusion Criteria:
- Pregnant or breast-feeding or intending to become pregnant during the study
- Have had chemotherapy (including purine analogs), rituximab, and other investigational agents within six weeks prior to entering the study. The patients cannot have received BRAF inhibitor therapy within 6 months of entering the study.
- Major surgery within 4 weeks prior to entering the study
- Invasive malignancy within the past 2 years prior to first study drug administration, except for adequately treated (with curative intent) basal or squamous cell carcinoma, melanoma, in situ carcinoma of the cervix, in situ ductal adenocarcinoma of the breast, in situ prostate cancer, or limited stage bladder cancer or other cancers from which the patient has been disease-free for at least 2 years
- Active HIV, hepatitis B and hepatitis C or any clinically significant history of liver disease. Hepatitis B prior infection is not a contraindication though will require therapy.
- Known hypersensitivity to any of the study drugs
- Patients with HCL that are BRAF V600E mutation negative
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Low dose Vemurafenib and Rituximab
Eligible patients will receive vemurafenib at a dose of 240 mg orally twice daily (b.i.d.) continuously for 8 weeks.
Rituximab 375 mg/m2 will be administered every 2 weeks for a total of 16 weeks.
The entire duration of treatment will be 16 weeks.
|
Vemurafenib 960 mg twice daily for 8 weeks with concurrent rituximab 375 mg/m2 every 2 weeks followed by maintenance consolidative rituximab 4 times every 2 weeks post-vemurafenib
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Complete Response
Time Frame: Up to 2 years from enrollment
|
Resolution of cytopenias and splenomegaly
|
Up to 2 years from enrollment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to hematologic response
Time Frame: Up to 2 years from enrollment
|
Days until resolution of cytopenias
|
Up to 2 years from enrollment
|
MRD Status
Time Frame: At 6 months, 1 year and 2 years from treatment
|
At the time of bone marrow assessment by testing for BRAFV600E mutation status
|
At 6 months, 1 year and 2 years from treatment
|
Relapse-Free Survival
Time Frame: From start of treatment until 2 years
|
Reapperance of Hairy-Cell related cytopenia
|
From start of treatment until 2 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Alan Saven, MD, Scripps Clinic
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Tiacci E, De Carolis L, Simonetti E, Capponi M, Ambrosetti A, Lucia E, Antolino A, Pulsoni A, Ferrari S, Zinzani PL, Ascani S, Perriello VM, Rigacci L, Gaidano G, Della Seta R, Frattarelli N, Falcucci P, Foa R, Visani G, Zaja F, Falini B. Vemurafenib plus Rituximab in Refractory or Relapsed Hairy-Cell Leukemia. N Engl J Med. 2021 May 13;384(19):1810-1823. doi: 10.1056/NEJMoa2031298.
- Grever M, Andritsos L, Banerji V, Barrientos JC, Bhat S, Blachly JS, Call T, Cross M, Dearden C, Demeter J, Dietrich S, Falini B, Forconi F, Gladstone DE, Gozzetti A, Iyengar S, Johnston JB, Juliusson G, Kraut E, Kreitman RJ, Lauria F, Lozanski G, Parikh SA, Park J, Polliack A, Ravandi F, Robak T, Rogers KA, Saven A, Seymour JF, Tadmor T, Tallman MS, Tam CS, Tiacci E, Troussard X, Zent C, Zenz T, Zinzani PL, Wormann B. Hairy cell leukemia and COVID-19 adaptation of treatment guidelines. Leukemia. 2021 Jul;35(7):1864-1872. doi: 10.1038/s41375-021-01257-7. Epub 2021 May 4.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 2, 2022
Primary Completion (Estimated)
January 1, 2025
Study Completion (Estimated)
January 1, 2025
Study Registration Dates
First Submitted
May 16, 2022
First Submitted That Met QC Criteria
May 19, 2022
First Posted (Actual)
May 24, 2022
Study Record Updates
Last Update Posted (Actual)
November 14, 2023
Last Update Submitted That Met QC Criteria
November 10, 2023
Last Verified
November 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Leukemia
- Leukemia, Hairy Cell
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antirheumatic Agents
- Antineoplastic Agents
- Immunologic Factors
- Antineoplastic Agents, Immunological
- Protein Kinase Inhibitors
- Rituximab
- Vemurafenib
Other Study ID Numbers
- IRB-21-7787
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
IPD Plan Description
Plan to publish aggregate data in manuscript
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hairy Cell Leukemia
-
National Cancer Institute (NCI)Active, not recruitingHairy Cell Leukemia | Recurrent Hairy Cell Leukemia | Hairy Cell Leukemia VariantUnited States
-
National Cancer Institute (NCI)RecruitingHairy Cell Leukemia | Hairy Cell Leukemia VariantUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingHairy Cell Leukemia | Recurrent Hairy Cell LeukemiaUnited States
-
Memorial Sloan Kettering Cancer CenterYale University; Dana-Farber Cancer InstituteActive, not recruitingLeukemia | Leukemia, Hairy Cell | Hairy Cell LeukemiaUnited States
-
Memorial Sloan Kettering Cancer CenterNational Cancer Institute (NCI); Northwestern University; Northwell Health; Dana-Farber... and other collaboratorsActive, not recruitingHairy Cell LeukemiaUnited States
-
MedImmune LLCCambridge Antibody TechnologyCompletedHairy Cell LeukemiaUnited States, Poland
-
National Cancer Institute (NCI)TerminatedHairy Cell LeukemiaUnited States
-
Jurgen BarthCompletedHairy Cell Leukemia (HCL)Germany
-
AstraZenecaApproved for marketingRelapsed/Refractory Hairy Cell Leukemia
-
National Cancer Institute (NCI)Not yet recruitingRecurrent Hairy Cell Leukemia | Recurrent Hairy Cell Leukemia Variant
Clinical Trials on Low dose vemurafenib plus rituximab
-
Yantai Yuhuangding HospitalRecruiting
-
Tata Memorial CentreRecruitingMedulloblastoma, WNT-activatedIndia
-
Shenzhen Beike Bio-Technology Co., Ltd.No.85 Hospital, Changning, Shanghai, ChinaCompleted
-
University of California, San FranciscoFerring PharmaceuticalsCompleted
-
Biohaven Pharmaceuticals, Inc.Dana-Farber Cancer InstituteRecruitingMultiple MyelomaUnited States
-
Dong-A ST Co., Ltd.CompletedOsteoarthritis, KneeKorea, Republic of
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingRecurrent Mantle Cell Lymphoma | Refractory Mantle Cell LymphomaUnited States
-
Emory UniversityNational Cancer Institute (NCI)TerminatedPneumonia | Coronavirus Infection in 2019 (COVID-19) | Severe Acute Respiratory Syndrome (SARS) PneumoniaUnited States
-
MedImmune LLCCompletedNon-alcoholic Fatty Liver Disease (NAFLD) | Non-alcoholic Steatohepatitis (NASH)United States, Puerto Rico
-
Beijing Northland Biotech. Co., Ltd.CompletedSafety and Efficacy Study of Thymosin Beta 4 in Patients With Acute Myocardial Infarction.InfarctionAcute Myocardial InfarctionChina